Kymera Therapeutics, Inc. KYMR
136.64 USD -2.22 (-1.60%)
At closeNov 10, 2026, 7:38 PM EST
140.00 +3.36 +2.46%
After hours · Nov 10, 7:38 PM ET
136.01 Day range 142.92
60.25 52-week range 142.92
- YTD
- +75.61%
- 1 year
- +123.05%
News
benzinga.com Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170 Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $139 to $170.- benzinga.com Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150 Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.
benzinga.com RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116 RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Sector Perform and raises the price target from $112 to $116.
benzinga.com BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139 BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $134 to $139.- benzinga.com Kymera Therapeutics Q3 EPS $(1.32) Misses $(1.27) Estimate Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.27) by 3.94 percent. This is a 40.43 percent decrease over losses…
- benzinga.com Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146 Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.
benzinga.com This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiate coverage: Outperform on American Express and Kymera, Overweight on Kratos, Hold on IBM and Neutral on Duos.
benzinga.com Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140 Raymond James analyst Thomas Deal initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $140.- benzinga.com Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150 Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $150.
- benzinga.com Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152 Stifel analyst Alex Thompson maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $132 to $152.
benzinga.com B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144 B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $123 to $144.- benzinga.com Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170 Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $170.
- benzinga.com Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151 Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $116 to $151.
benzinga.com Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139 Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.- benzinga.com Kymera Therapeutics Q2 EPS $(0.62) Beats $(0.72) Estimate, Sales $65.000M Beat $31.165M Estimate Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 34.74 percent increase over losses of…
benzinga.com This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.
benzinga.com Deutsche Bank Initiates Coverage On Kymera Therapeutics with Hold Rating, Announces Price Target of $120 Deutsche Bank analyst David Hoang initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Hold rating and announces Price Target of $120.
benzinga.com Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $135 Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $125 to $135.- benzinga.com Mizuho Maintains Outperform on Kymera Therapeutics, Raises Price Target to $140 Mizuho analyst Joseph Catanzaro maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $120 to $140.
benzinga.com RBC Capital Downgrades Kymera Therapeutics to Sector Perform, Raises Price Target to $115 RBC Capital analyst Brian Abrahams downgrades Kymera Therapeutics (NASDAQ:KYMR) from Outperform to Sector Perform and raises the price target from $106 to $115.- benzinga.com B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125 B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $110 to $125.
benzinga.com Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $136 Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $116 to $136.- benzinga.com B. Riley Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $155 B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $117 to $155.
- benzinga.com Canaccord Genuity Maintains Buy on Kymera Therapeutics, Raises Price Target to $129 Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $106 to $129.
benzinga.com Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program Kymera Therapeutics shares surged after completing KT-621 Phase 2b enrollment early, accelerating data timing and Phase 3 plans.- benzinga.com BTIG Reiterates Buy on Kymera Therapeutics, Maintains $134 Price Target BTIG analyst Jeet Mukherjee reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintains $134 price target.
benzinga.com Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High U.S. stocks traded mostly higher, with the Nasdaq Composite down 0.1%. Industrials jumped 2.5%, while consumer discretionary fell 1.1%. Core PCE rose 3.4% in May.
benzinga.com Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial results, shares rose 17.1%; other big stocks also gained.- benzinga.com Kymera Therapeutics Completes Enrollment In Global BROADEN2 Phase 2b Trial Of KT-621, Oral STAT6 Degrader, For Treatment Of Moderate To Severe Atopic Dermatitis BROADEN2 enrollment completed nearly six months ahead of anticipated timelinesKT-621 Phase 3 trials in AD planned to initiate by mid-2027KT-621 BREADTH Phase 2b asthma trial ongoing, with data…
- benzinga.com Kymera Therapeutics Appoints Felix J. Baker Board Chairman, Succeeding Bruce Booth Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the…
benzinga.com Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM, ORKA, CHRN, UMC,…- benzinga.com Kymera Therapeutics Announces Results From Its Phase 1 Study Of KT-621 In Healthy Japanese Adults Were Shared At The Japanese Dermatological Association Annual Meeting, June 11-14 "The consistency we've demonstrated across KT-621 Phase 1 studies, from robust STAT6 degradation to a favorable safety profile, reflects the strong fidelity of translation of this unique approach…
- benzinga.com Kymera Therapeutics Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Evaluating KT-485, Oral, Potent And Selective IRAK4 Degrader, In Adult Healthy Volunteers And HS Patients First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from SanofiWATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics,…
benzinga.com Earnings Scheduled For April 30, 2026 
benzinga.com Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…- benzinga.com Earnings Scheduled For February 26, 2026
benzinga.com Broadcom To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday 
benzinga.com Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com Market-Moving News for December 8th FULC: 66% | Fulcrum Therapeutics Announced Saturday, Initial Results From 20 mg Dose Cohort Of The Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease; Clear Dose-response Observed, With…
benzinga.com Why Confluent Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket 
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com Earnings Scheduled For August 11, 2025
benzinga.com Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD.
benzinga.com Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Earnings Scheduled For May 9, 2025
benzinga.com Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio? Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics.- benzinga.com Earnings Scheduled For February 27, 2025